JP2022545682A - ＩｇＭグリコバリアント - Google Patents

ＩｇＭグリコバリアント Download PDF

Info

Publication number
JP2022545682A
JP2022545682A JP2022512306A JP2022512306A JP2022545682A JP 2022545682 A JP2022545682 A JP 2022545682A JP 2022512306 A JP2022512306 A JP 2022512306A JP 2022512306 A JP2022512306 A JP 2022512306A JP 2022545682 A JP2022545682 A JP 2022545682A
Authority
JP
Japan
Prior art keywords
igm
seq
amino acid
chain
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2022512306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545682A5 (https=
Inventor
ブルース ケイト
ディーン エン
ラメシュ バリガ
Original Assignee
アイジーエム バイオサイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイジーエム バイオサイエンシズ インコーポレイテッド filed Critical アイジーエム バイオサイエンシズ インコーポレイテッド
Publication of JP2022545682A publication Critical patent/JP2022545682A/ja
Publication of JP2022545682A5 publication Critical patent/JP2022545682A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022512306A 2019-08-23 2020-08-21 ＩｇＭグリコバリアント Ceased JP2022545682A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962891263P 2019-08-23 2019-08-23
US62/891,263 2019-08-23
PCT/US2020/047495 WO2021041250A1 (en) 2019-08-23 2020-08-21 Igm glycovariants

Publications (2)

Publication Number Publication Date
JP2022545682A true JP2022545682A (ja) 2022-10-28
JP2022545682A5 JP2022545682A5 (https=) 2023-08-16

Family

ID=74684266

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022512306A Ceased JP2022545682A (ja) 2019-08-23 2020-08-21 ＩｇＭグリコバリアント

Country Status (11)

Country Link
US (1) US20220306760A1 (https=)
EP (1) EP4017533A4 (https=)
JP (1) JP2022545682A (https=)
KR (1) KR20220050166A (https=)
CN (1) CN114269380A (https=)
AU (1) AU2020337333A1 (https=)
BR (1) BR112022003282A2 (https=)
CA (1) CA3149350A1 (https=)
IL (1) IL290253A (https=)
MX (1) MX2022002239A (https=)
WO (1) WO2021041250A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3560954T3 (pl) 2014-04-03 2021-12-13 Igm Biosciences, Inc. Zmodyfikowany łańcuch J
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
EP3355913B1 (en) 2015-09-30 2024-10-30 IGM Biosciences, Inc. Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
MX2021014973A (es) 2019-06-07 2022-04-18 Adimab Llc Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso.
EP4377360A4 (en) * 2021-09-17 2025-10-15 Adimab Llc Anti-cd3 antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019502694A (ja) * 2015-12-18 2019-01-31 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 二特異性抗体基幹

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00832B (me) * 2007-03-22 2012-03-20 Ucb Biopharma Sprl Vezivni proteini uključujući antitjela, derivate antitjela i fragmente antitjela, koji specifično vezuju cd154 i njihova upotreba
CA2780221A1 (en) * 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
PL3560954T3 (pl) * 2014-04-03 2021-12-13 Igm Biosciences, Inc. Zmodyfikowany łańcuch J
EP3355913B1 (en) * 2015-09-30 2024-10-30 IGM Biosciences, Inc. Binding molecules with modified j-chain
WO2018136825A1 (en) * 2017-01-19 2018-07-26 Cedars-Sinai Medical Center Highly multiplexed and mass spectrometry based methods to measuring 72 human proteins
MA49279A (fr) * 2017-03-22 2020-02-05 Hoffmann La Roche Compositions d'anticorps optimisées pour le traitement de troubles oculaires
CA3083363A1 (en) * 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019502694A (ja) * 2015-12-18 2019-01-31 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 二特異性抗体基幹

Also Published As

Publication number Publication date
IL290253A (en) 2022-04-01
WO2021041250A1 (en) 2021-03-04
EP4017533A1 (en) 2022-06-29
CA3149350A1 (en) 2021-03-04
EP4017533A4 (en) 2024-03-27
US20220306760A1 (en) 2022-09-29
MX2022002239A (es) 2022-03-22
CN114269380A (zh) 2022-04-01
KR20220050166A (ko) 2022-04-22
BR112022003282A2 (pt) 2022-05-24
AU2020337333A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
US20240124584A1 (en) Igm fc and j-chain mutations that affect igm serum half-life
US20230203173A1 (en) Tumor necrosis factor (tnf) superfamily receptor igm antibodies and uses thereof
JP2022545682A (ja) ＩｇＭグリコバリアント
US20230203119A1 (en) Immunostimulatory multimeric binding molecules
JP7585305B2 (ja) 多量体の二重特異性抗ｃｄ１２３結合分子及びその使用
US20220372142A1 (en) Multimeric antibodies with enhanced selectivity for cells with high target density
JP2023522962A (ja) Ｐｄ－１アゴニスト多量体結合分子
US20240076392A1 (en) Anti-cd123 binding molecules and uses thereof
CA3091144C (en) Igm fc and j-chain mutations that affect igm serum half-life
HK1242348A1 (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
HK1242348B (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230807

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241225

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250217

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20250623